Objectives. This study aimed to estimate the prevalence of US-detected tenosynovitis in RA patients in clinical remission and to explore its clinical correlates.
Introduction
Remission is the current target of treatment in patients with RA [1] . Nevertheless, the definition of remission in RA is still a matter of debate. Ideally, remission may be defined as a condition characterized by the absence of clinically detectable disease activity, the arrest of radiographic progression and the normalization or maximal improvement of physical function [2] . However, the assessment of remission is frequently a challenge in clinical practice. Subclinical disease activity may be present even if a patient fits the proposed definitions of clinical remission, leading to joint damage progression [36] and disease flare [6, 7] .
Imaging, in particular musculoskeletal ultrasonography (MSUS), is useful in overcoming the limitations of clinical measures of disease activity [3, 4, 8] . Even in the absence of clinically detectable joint swelling, imaging can reveal synovial effusion and synovial hypertrophy using greyscale (GS) mode and synovial active inflammation using the power Doppler (PD) technique [5] . Moreover, MSUS is reliable and sensitive to change and can provide diagnostic and prognostic data in terms of risk of flare, disability and anatomical damage progression at different stages of RA [7, 911] . For these reasons, several MSUS studies performed in RA patients in clinical remission have focused on assessing subclinical joint synovitis to identify patients with subclinical disease activity. In several studies, the majority of patients in clinical remission showed persistent GS (5090%) and PD synovitis (4060%) [10, 12] . Although GS synovitis has been reported to be poorly associated with clinical and radiological outcomes [4, 13] , PD occurring in RA patients in clinical remission leads to a clinically meaningful increased risk of flare over time, with odds ratios (ORs) ranging from 3 to 10, suggesting that PD may help in identifying patients with subclinical disease [9, 14] . Furthermore, the association of PD synovitis with future occurrence of disability and structural damage strengthens the plausibility of this association and the validity of such a measure [15] . However, it should be taken into account that RA inflammation may be located not only within the joints, but also at the level of the periarticular synovial structures such as tendon sheaths. Indeed, as well as synovitis, tenosynovitis is a typical manifestation of RA, which associates with pain and erosive evolution in early disease [11, 16] , tendon ruptures [16, 17] and disability. In spite of this, very few data are available on both its prevalence in RA patients and its prognostic significance in the subpopulation of RA patients in clinical remission [18, 19] . This lack of information might be partially due to the difficulty in differentiating between articular and tendon swelling by clinical examination. In this context, MSUS may be the best imaging method to characterize tenosynovitis and to evaluate its frequency and prognostic significance in RA patients in clinical remission.
On this basis, the MSUS Study Group of the Italian Society for Rheumatology (SIR) prioritized its research activities on assessment of the prevalence and clinical significance of MSUS-detected tenosynovitis in RA patients in clinical remission, launching a multicentre study, the Sonographic Tenosynovitis Assessment in Rheumatoid Arthritis Patients in Remission (STARTER) study. The objective of this study was to determine the prevalence of US tenosynovitis (and synovitis) at baseline in RA patients in clinical remission and its association with unstable remission, function and damage.
Methods

Patient and study design
This is a cross-sectional analysis of the STARTER study, which is a multicentre observational study promoted by the MSUS Study Group of the SIR and includes 25 Italian rheumatology centres, recruited on voluntary basis. In this context, consecutive patients classified as RA according www.rheumatology.oxfordjournals.org to the 1987 ACR criteria or 2010 ACR/EULAR criteria and in clinical remission were recruited between October 2013 and June 2014. Patients were considered eligible if they met at least one of the following remission criteria at the screening visit: 28-joint DAS (DAS28) < 2.6 [20] , Simplified Disease Activity Index (SDAI) 43.3 [21] , Clinical Disease Activity Index (CDAI) 42.8 [22] , ACR/EULAR Boolean definition [21] , absence of swollen/tender joints on 28 joints [23] or remission based on clinical evaluation of an expert rheumatologist [3] . All patients underwent a complete clinical assessment and an MSUS examination.
The STARTER study was approved by the local ethics committee for each of the participating sites. Written informed consent was obtained from all participants. This analysis did not require separate ethical approval.
Clinical assessment
For each patient, complete demographic (age, sex, type of occupational activity, smoking habit), anamnestic (date of RA onset and diagnosis, disease and remission duration, co-morbidities, previous and current therapy for RA) and clinimetric [weight and height, the Italian version of the HAQ [24] , flare questionnaire (FQ) [25, 26] , duration of morning stiffness, visual analogue scale (VAS) for joint pain, physician global assessment, patient global assessment and global health] data were collected; laboratory data such as ESR, CRP, RF and ACPA positivity and titres were recorded. In addition, a standard 28-joint count was performed. Plain radiographs of the hands, wrists and feet were also collected. The clinical assessment was performed by a clinical rheumatologist at each centre who was blinded to the US results.
Outcome measures
Unstable remission disease was set as the primary outcome of the analysis and defined according to the FQ value over its median value (3) in our study sample. Secondary outcomes included functional disability, evaluated by the Italian version of the HAQ score >0.5 [27] , and bone damage, defined as the presence of typical bone erosions at baseline radiographs as reported by the investigator.
Ultrasonographic assessment
All ultrasonographers participating in the study were experts in MSUS and were selected on the basis of an interand intra-observer reliability exercise against a reference standard (AI) on static images using an e-learning platform. Only ultrasonographers for whom the results of the reliability assessment were from good to excellent (weighted k 50.7) [28] were allowed to participate in the study. In addition, the equipment level available at the different sites was assessed and only high-level US machines (MyLab 70XVG, MyLab Twice, Logiq9, LogiqE9) with high-frequency linear probes (1418 MHz) were allowed. High-level US machines were provided by Esaote (Genoa, Italy) to those investigators who passed the reliability exercise test but who did not have an adequate US machine at their site. MSUS examination was performed according to the EULAR guidelines [29] . In each rheumatology unit, the MSUS evaluations were performed by a single rheumatologist expert in MSUS who was blinded to the clinical data.
The MSUS tendon scanning protocol included multiplanar longitudinal and transverse scanning of flexor and extensor tendon sheaths of the wrist and fingers bilaterally and longitudinal scanning of the dorsal aspect of the wrist (radiocarpal and mid-carpal joint) with joints in a neutral position. Specifically, extensor tendons of the wrist were examined from the Lister's tubercle to the metacarpal bones. Flexor tendons at the wrist were examined from the proximal edge of the carpal tunnel to the palm of the hand, while the flexor radialis carpi tendon was examined in its pre-insertional and insertional tract where the synovial sheath is present. Flexor digitorum tendons and flexor pollicis longus tendon were examined from the palm of the hand to the distal phalanx. The MSUS joint scanning protocol included multiplanar longitudinal scanning of the dorsal aspects of the MCP joints bilaterally and longitudinal scanning of the palmar aspects of the PIP joints bilaterally. Tenosynovitis, joint effusion and synovial hypertrophy were identified according to OMERACT definitions [30] . In particular, tenosynovitis was defined as the presence of hypoechoic or anechoic thickened tissue with or without fluid within the tendon sheath, which is seen in two perpendicular planes and which may exhibit PD signal [30] .
Synovial and tenosynovial PD were evaluated by selecting a region of interest that included the bony margins, joint space and a variable view of surrounding tissues, using abundant US gel to avoid pressure on the tissues. US machine settings were adjusted to the lowest permissible pulse repetition frequency (500750 Hz) to maximize sensitivity. Doppler frequency was set high (7.514.3 MHz) to optimize the detection of flow at the level of small joints and superficial tissues. Colour gain was set just below the level that caused the appearance of noise artefacts. In all findings, flow was confirmed in two perpendicular planes.
GS tenosynovitis was semi-quantitatively scored from 0 to 3 (0 = normal; 1 = mild; 2 = moderate; 3 = marked); PD tenosynovitis signal was also assessed using a 03 semi-quantitative score (0 = absence or minimal flow; 1 = mild: single vessel signal; 2 = moderate: confluent vessels; 3 = marked: vessel signals in >50% of the tenosynovial tissue) [31] . US-detected synovitis and joint effusion were scored together according to a 03 semi-quantitative simplified score [32] and PD synovitis was also semiquantitatively graded from 0 to 3, as previously reported ( Fig. 1 ) [33] . At the end of each US exam, total scores for GS tenosynovitis, PD tenosynovitis, GS synovitis and PD synovitis were calculated by summing the scores detected at different sites. We defined GS tenosynovitis remission as a total score in GS tenosynovitis of 0, PD tenosynovitis remission as a total score in PD tenosynovitis of 0, GS synovitis remission as a total score in GS synovitis of 0 and PD synovitis remission as a total score in PD synovitis of 0. Representative scan images of each MSUS exam were recorded.
Statistical analysis
The prevalence of tenosynovitis was evaluated on the basis of different remission criteria and presented with its corresponding exact 95% CI. The association between demographic, clinical, serological and treatment variables was explored by the chi-square or Wilcoxon test based on the variable type and distribution and correlation using Spearman's r coefficient.
The cross-sectional relationship between the presence of GS tenosynovitis/synovitis, PD tenosynovitis/synovitis and outcome variables (FQ positivity, HAQ score and erosive damage) were evaluated by logistic models and presented as ORs and 95% CIs, both crude and adjusted for pre-specified confounders, coded as follows: age (quartiles: 1847, 4856, 5765, 566 years), sex (categorical), disease duration (quartiles: 03.99, 47.49, 7.513.49, 513.5 years), remission duration (07.9, 811.9, 1223.9, 524 months), musculoskeletal co-morbidities (dichotomous), RF (dichotomous), ACPA (dichotomous), concurrent DMARDs (dichotomous), biologics (dichotomous), NSAIDs (dichotomous) and systemic and locally injected glucocorticoids (dichotomous) [14, 18, 3437] .
Study data were collected and managed using Research Electronic Data Capture. Research Electronic Data Capture is a free, secure, Web-based application designed to support data capture for research studies, providing an intuitive interface for validated data entry, audit trails for tracking data manipulation and export procedures, automated export procedures for seamless and anonymous data downloads to common statistical packages and procedures for importing data from external sources [38] . Analyses were performed using STATA software (2009, release 11; StataCorp, College Station, TX, USA).
Results
Participants and descriptive data
A total of 427 patients were included in the analysis: complete history, clinical, clinimetric and serological characteristics of the study population are described in Table 1 (Table 2) . No significant differences were found in the proportion of patients in remission according to MSUS variables within other clinical remission criteria (CDAI, SDAI and ACR/EULAR Boolean definition). The details of the distribution of MSUS variables are reported in supplementary Table S1 and Fig. S1 , available at Rheumatology Online.
Regarding MSUS synovitis, 58% of patients in DAS28 remission and 62% of patients in remission as per the ACR/EULAR Boolean definition were in PD synovitis remission; 29% of patients in DAS28 remission and 32% of patients in remission as per the ACR/EULAR definition were in GS synovitis remission (Table 2) . Concerning GS tenosynovitis/PD tenosynovitis, the involvement of the sixth extensor tendon compartment of the wrist bilaterally was most commonly observed, while GS synovitis/PD synovitis was mostly found at wrist and second and third MCP joints bilaterally, with a predominance of right side involvement. Other common sites of GS tenosynovitis/PD tenosynovitis detection were the fourth extensor tendon compartment of the wrist bilaterally, the flexor tendons of the second finger bilaterally and the flexor tendons of the third and fourth fingers of the right hand (supplementary Tables S2 and S3 , available at Rheumatology Online).
Clinical correlates of US tenosynovitis and US synovitis
As shown in Table 3 , shorter remission duration and higher swollen joint count were significantly and positively associated with PD and GS tenosynovitis. Higher BMI, RF positivity, ACPA positivity and FQ score were significantly and positively associated with PD tenosynovitis, while a significant positive association was found between GS tenosynovitis and older age, higher CDAI and higher SDAI scores. Similar results were found also for PD and GS synovitis, which were significantly and positively associated with corticosteroid therapy, RF and ACPA positivity, erosive RA, higher swollen joint count and higher CDAI and SDAI scores (Table 4) . Also, GS synovitis was significantly and positively associated with male sex, older age and shorter remission duration. Analysing clinical correlates of MSUS variables as continuous variables, morning stiffness was significantly associated with PD tenosynovitis (r = 0.29, P < 0.05), while PD synovitis did not (r = À0.01, P > 0.05).
Cross-sectional associations of US tenosynovitis and US synovitis with FQ, function and damage Exploring associations of MSUS variables with potentially relevant outcome, tenosynovitis associated with FQ score, with a 2-fold higher probability of having a higher score in patients with the presence of PD tenosynovitis, even after adjustment for pre-specified confounders. No significant associations were found for GS tenosynovitis and synovitis, both PD and GS (Table 5) .
Neither tenosynovitis nor synovitis US variables showed any significant association with the presence of at least mild functional disability, as measured by the HAQ. Similar results were obtained restricting the sample to short remission duration (<12 months) and to active workers. The presence of radiographic erosions showed a significant association with synovial MSUS variables, both GS and PD synovitis, particularly GS synovitis, which showed a 2-fold increase of the probability of erosive disease, still significant even after adjusting for the full set of confounders.
Discussion
This multicentre study was designed to evaluate the prevalence of US-detected tenosynovitis in RA patients in clinical remission and to evaluate its clinical correlates and its association with the risk of flare, worsening of functional disability and damage. Although tenosynovitis is recognized as a typical extra-articular RA manifestation, few data are present in the literature on its real prevalence, and the published data on its prognostic significance in RA patients in clinical remission are even more limited [39, 40] .
The diagnostic and prognostic value of US-detected articular synovitis have been demonstrated in the last few years. In particular, in the subpopulation of RA patients in clinical remission, great effort was made in defining the prognostic significance of ongoing PD-positive synovitis, leading to the conclusion that the definition of remission status should be reserved for patients who are both in a state of clinical remission defined by clinimetric indexes and show the absence of synovitis on imaging studies [8] . In this regard, the STARTER study contributes in better defining imaging remission, studying for the first time systematically US-detected tenosynovitis of the hand and wrist joints of RA patients in clinical remission.
The results of these analyses confirm the potential role of US tenosynovial-targeted assessment in RA patients in clinical remission. To the best of our knowledge, STARTER is one of the largest cohorts of RA patients in clinical remission assessed by MSUS ever reported, including 427 patients. In our study sample we found a significant proportion of patients with the presence of GS tenosynovitis (52.5%) and PD tenosynovitis (22.7%), while the prevalence of GS synovitis (71.6%) and PD synovitis (42%) were in agreement with previous studies [10, 12] .
The lower prevalence of tenosynovitis makes this US feature a possibly more specific tool to identify subclinical inflammation compared with US synovitis. Indeed, although PD synovitis is very sensitive in predicting shortterm flare, it has a low positive predictive value: a large number of RA patients in clinical remission with PD synovitis do not relapse, mainly in long-standing disease [36] . The results of our study suggest that PD tenosynovitis could be more specific than PD synovitis in identifying patients with ongoing active disease and unstable clinical remission, as that was the only US variable significantly associated with FQ.
Furthermore, the combined synovial and tenosynovial US assessment could be useful to stratify patients according to the type and site of subclinical inflammation. In fact, in our population, PD tenosynovitis significantly correlated with two patient-reported outcomes (morning stiffness and FQ), while synovial US findings did not: in this context, tenosynovial involvement could explain symptoms of the subpopulation of RA patients in clinical remission characterized by mild relapses and unstable remission but not associated with severe RA in terms of disability or damage. On the other hand, our study confirms the association between erosions and the presence of subclinical US synovitis, in both the GS and PD modes.
Among the multiple and somehow predictable associations between clinical factors and US-detected tenosynovitis and synovitis, one of the most interesting refers to RF and ACPA. The association between RF positivity and clinical tenosynovitis was already evidenced in a previous study [41] . In our research we found a strong association between PD tenosynovitis/synovitis and RF and ACPA positivity, while this association was lacking for GS tenosynovitis and was even weaker for GS synovitis. Given the well-established prognostic value of RF and ACPA in RA patients, their association with imaging disease activity indexes suggests a link between these risk factors and a higher risk of subclinical active disease.
The results of the present study should be interpreted in consideration of certain limitations. In this phase the study had a cross-sectional design, making it impossible to draw any conclusions in terms of prognosis. Prospective results from this study will answer this question. Patients were consecutively-not randomly-enrolled in rheumatology clinics with expertise in US, potentially introducing a selection bias. Our cohort was apparently a homogeneous cohort of RA patients in clinical remission, as it included patients in remission according to different criteria and under different treatments. To handle this variability, an adequate sample size was planned. Given the multisite nature of our study, there was the risk of differences in MSUS and clinical assessment leading to highly inhomogeneous data collection. To overcome this drawback, ultrasonographers were trained and then selected by an interobserver reliability exercise that showed a high reliability rate. Also, guidelines with specific instructions on how to perform a correct clinical assessment as per the protocol were distributed to the clinical rheumatologists. The residual methodological heterogeneity might limit the precision of the results, but it is unlikely that it biases the results, supporting the generalizability of the conclusions. As well as several previous imaging studies on tenosynovitis, our scanning protocol included only hands and wrists [1618, 4244] , excluding some potentially relevant structures in RA, such as, for example, the tibialis posterior tendon [45, 46] . This might decrease the sensitivity of our US assessment, but did not threaten the validity of our results, and clearly increased the feasibility of a large sample study and transferability into practice. Finally, the FQ instrument was used as an outcome www.rheumatology.oxfordjournals.org measure, although this questionnaire was still not fully validated and there were no fully validated references for interpreting the FQ [26] . The FQ was developed to identify past or present RA flare, so it describes unstable remission in a setting of cross-sectional evaluation.
Despite these limitations the results of the STARTER study indicate that US-detected tenosynovitis could be a useful tool for rheumatologists to better define remission as well as a subset of RA patients in clinical remission. Tenosynovitis-targeted US evaluation should be a part of the assessment of RA patients in clinical remission.
TABLE 5
Cross-sectional associations of US tenosynovitis and US synovitis with flare, function and damage 
